Zentalis Pharmaceuticals (ZNTL) Announces Proposed 3.75M Share Common Offering

Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) today announced the commencement of a proposed underwritten public offering of 3,750,000 shares of its common stock. All shares of common stock to be sold in the proposed offering will be sold by Zentalis. Zentalis also expects to grant the underwriters a 30-day option to purchase up to an additional 562,500 shares of common stock at the public offering price, less underwriting discounts and commissions.

Morgan Stanley, Jefferies, SVB Leerink and Guggenheim Securities are acting as joint book-running managers for the offering.

You May Also Be Interested In

• ADARx Pharmaceuticals files for proposed IPO
• GLJ Research on Tesla (TSLA): 'Sell-the-news'
• Oracle (ORCL) PT Raised to $210 at Morgan Stanley